Journal
ONCOGENE
Volume 19, Issue 53, Pages 6144-6151Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1204000
Keywords
antibody therapy; radioimmunotherapy; bispecific antibodies
Funding
- NCI NIH HHS [CA06927, CA65559, CA50633] Funding Source: Medline
Ask authors/readers for more resources
Antibody-based therapy of human cancers has led to several remarkable outcomes, particularly in the therapy of breast cancer and lymphoma. Many solid tumors have proven less responsive, due in part to difficulties in the tumor-selective delivery of antibodies and potential cytolytic effecters. However, antibodies that directly perturb signaling mechanisms in cells derived from epithelial malignancies have shown benefit; examples include antibodies directed against the extracellular domains of HER2/neu and epidermal growth factor receptor. A long-term goal of immunotherapy has been to induce anti-tumor inflammatory responses that can directly cause tumor regression or induct adaptive responses against tumor-related antigens. This review focuses on the use of antibodies to provide a means for initiating anti-tumor immune responses, and on the use of antibodies as delivery vehicles of radionuclides.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available